https://scholars.lib.ntu.edu.tw/handle/123456789/507234
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Tseng J.-S. | en_US |
dc.contributor.author | KANG-YI SU | en_US |
dc.contributor.author | Yang T.-Y. | en_US |
dc.contributor.author | Chen K.-C. | en_US |
dc.contributor.author | Hsu K.-H. | en_US |
dc.contributor.author | Chen H.-Y. | en_US |
dc.contributor.author | Tsai C.-R. | en_US |
dc.contributor.author | SUNG-LIANG YU | en_US |
dc.contributor.author | Chang G.-C. | en_US |
dc.creator | Tseng J.-S.;Kang-Yi Su;Yang T.-Y.;Chen K.-C.;Hsu K.-H.;Chen H.-Y.;Tsai C.-R.;Yu S.-L.;Chang G.-C. | - |
dc.date.accessioned | 2020-06-30T08:10:02Z | - |
dc.date.available | 2020-06-30T08:10:02Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/507234 | - |
dc.description.abstract | Different growth kinetics occurring between the sensitive and T790M-containing cells may result in the repopulation of tumor cells over time. Little information has yet been uncovered on whether rebiopsy timing influences the T790M detection rate. We enrolled a total of 98 epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients, who had a history of acquired resistance to EGFR-tyrosine kinase inhibitor (TKI) and available rebiopsy tumor specimens for reassessment of EGFR mutations. Rebiopsy was performed at the time of first EGFR-TKI progression in 54 patients (55.1%); for the other 44 patients (44.9%), rebiopsy was done with an interval from first EGFR-TKI progression (median 470.5 days, range 46-1742 days). Our results indicated that rebiopsy timing did not influence the detection rate of T790M and that the mutation could be identified in patients with a long EGFR-TKIfree interval. For patients without suitable lesions for rebiopsy at the time of EGFRTKI progression, an attempt to rebiopsy should be considered during the subsequent treatment courses. | - |
dc.relation.ispartof | Oncotarget | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | afatinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; methionine; osimertinib; threonine; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; adult; amino acid substitution; Article; cancer patient; cancer resistance; controlled study; cytopathology; female; histopathology; human; human tissue; lung adenocarcinoma; lung biopsy; lung rebiopsy; major clinical study; male; mutational analysis; progression free survival; survival time; time to treatment; treatment response; adenocarcinoma; aged; antagonists and inhibitors; biopsy; disease exacerbation; drug resistance; enzymology; genetics; lung tumor; middle aged; mutation; pathology; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor | - |
dc.title | The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.18632/oncotarget.10351 | - |
dc.identifier.pmid | 27384480 | - |
dc.identifier.scopus | 2-s2.0-84982802734 | - |
dc.relation.pages | 48059-48069 | - |
dc.relation.journalvolume | 7 | - |
dc.relation.journalissue | 30 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Medical Device and Imaging | - |
crisitem.author.orcid | 0000-0002-6538-9526 | - |
crisitem.author.orcid | 0000-0003-4535-9036 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。